logo-loader
viewAstraZeneca

US and European regulators accept AstraZeneca's cancer drug applications

The US FDA has accepted AstraZeneca’s biologics licence application for Moxetumomab Pasudotox while the European Medicines Agency will review the company's marketing authorisation application for Lynparza

AstraZeneca
Lynparza is used to treat patients who have metastatic breast cancer

US and European regulators have accepted applications for AstraZeneca PLC ‘s (LON:AZN) cancer treatments Moxetumomab Pasudotox and Lynparza .

AstraZeneca said the US Food and Drug Administration (FDA) has accepted the biologics license application for Moxetumomab Pasudotox, used to treat hairy-cell leukaemia in adults.

READ: AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

The FDA has also granted the medicine priority-review status.

The European Medicines Agency will review AstraZeneca’s marketing authorisation application for Lynparza, representing the first regulatory submission for a poly ADP-ribose polymerase inhibitor for breast cancer in Europe.

Lynparza is used for patients who have metastatic breast cancer and have been treated with chemotherapy.

Shares in AstraZeneca fell 0.7% to 4,858p in morning trading.

 

Quick facts: AstraZeneca

Price: 7500 GBX

LSE:AZN
Market: LSE
Market Cap: £98.41 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pan African Resources 'builds solid platform' to deliver on...

Pan African Resources plc's (LON:PAF) chief executive Cobus Loots tells Proactive London's Andrew Scott they're on track to deliver their full-year production guidance of 185,000 ounces. In the six months to the end of December 2019 PAF's gold sales increased by 14.7% to 92,941...

30 minutes ago

2 min read